These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33199442)

  • 1. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes.
    Jachs M; Hartl L; Schaufler D; Desbalmes C; Simbrunner B; Eigenbauer E; Bauer DJM; Paternostro R; Schwabl P; Scheiner B; Bucsics T; Stättermayer AF; Pinter M; Trauner M; Mandorfer M; Reiberger T
    Gut; 2021 Sep; 70(9):1758-1767. PubMed ID: 33199442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death.
    Jachs M; Hartl L; Simbrunner B; Bauer D; Paternostro R; Scheiner B; Schwabl P; Stättermayer AF; Pinter M; Eigenbauer E; Quehenberger P; Trauner M; Reiberger T; Mandorfer M
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1362-1373.e6. PubMed ID: 34256145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.
    Costa D; Simbrunner B; Jachs M; Hartl L; Bauer D; Paternostro R; Schwabl P; Scheiner B; Stättermayer AF; Pinter M; Trauner M; Mandorfer M; Reiberger T
    J Hepatol; 2021 Apr; 74(4):819-828. PubMed ID: 33075344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.
    Mookerjee RP; Pavesi M; Thomsen KL; Mehta G; Macnaughtan J; Bendtsen F; Coenraad M; Sperl J; Gines P; Moreau R; Arroyo V; Jalan R;
    J Hepatol; 2016 Mar; 64(3):574-82. PubMed ID: 26519600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices.
    Paternostro R; Becker J; Hofer BS; Panagl V; Schiffke H; Simbrunner B; Semmler G; Schwabl P; Scheiner B; Bucsics T; Bauer D; Binter T; Trauner M; Mandorfer M; Reiberger T
    Dig Liver Dis; 2022 Apr; 54(4):500-508. PubMed ID: 34799282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of beta-blockers on multiple haemodynamics in cirrhosis: A cross-over study by MR-imaging and hepatic vein catheterization.
    Danielsen KV; Nabilou P; Wiese SS; Hove JD; Bendtsen F; Møller S
    Liver Int; 2023 Oct; 43(10):2245-2255. PubMed ID: 37387503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease.
    Simbrunner B; Villesen IF; Königshofer P; Scheiner B; Bauer D; Paternostro R; Schwabl P; Timelthaler G; Ramazanova D; Wöran K; Stift J; Eigenbauer E; Stättermayer AF; Marculescu R; Pinter M; Møller S; Trauner M; Karsdal M; Leeming DJ; Reiberger T; Mandorfer M
    Liver Int; 2022 Nov; 42(11):2501-2512. PubMed ID: 35822301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease.
    Balcar L; Krawanja J; Scheiner B; Paternostro R; Simbrunner B; Semmler G; Jachs M; Hartl L; Stättermayer AF; Schwabl P; Pinter M; Szekeres T; Trauner M; Reiberger T; Mandorfer M
    JHEP Rep; 2023 Apr; 5(4):100682. PubMed ID: 36873421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis.
    Reiberger T; Ferlitsch A; Payer BA; Pinter M; Homoncik M; Peck-Radosavljevic M;
    J Gastroenterol; 2012 May; 47(5):561-8. PubMed ID: 22170417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study.
    Kang SH; Lee M; Kim MY; Lee JH; Jun BG; Kim TS; Choi DH; Suk KT; Kim YD; Cheon GJ; Kim DJ; Baik SK
    Hepatol Int; 2021 Apr; 15(2):424-436. PubMed ID: 33860898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.
    Reiberger T; Ferlitsch A; Payer BA; Mandorfer M; Heinisch BB; Hayden H; Lammert F; Trauner M; Peck-Radosavljevic M; Vogelsang H;
    J Hepatol; 2013 May; 58(5):911-21. PubMed ID: 23262249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response.
    Simbrunner B; Caparrós E; Neuwirth T; Schwabl P; Königshofer P; Bauer D; Marculescu R; Trauner M; Scheiner B; Stary G; Mandorfer M; Reiberger T; Francés R
    Hepatol Int; 2023 Aug; 17(4):1045-1056. PubMed ID: 36881247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes impairs the haemodynamic response to non-selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation.
    Paternostro R; Jachs M; Hartl L; Simbrunner B; Scheiner B; Bauer D; Schwabl P; Semmler G; Trauner M; Mandorfer M; Reiberger T
    Aliment Pharmacol Ther; 2023 Oct; 58(8):805-813. PubMed ID: 37519146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease.
    Pomej K; Scheiner B; Balcar L; Nussbaumer RJ; Weinzierl J; Paternostro R; Simbrunner B; Bauer D; Pereyra D; Starlinger P; Stättermayer AF; Pinter M; Trauner M; Quehenberger P; Reiberger T; Mandorfer M
    Dig Liver Dis; 2022 Oct; 54(10):1376-1384. PubMed ID: 35871985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower free triiodothyronine (fT3) levels in cirrhosis are linked to systemic inflammation, higher risk of acute-on-chronic liver failure, and mortality.
    Hartl L; Simbrunner B; Jachs M; Wolf P; Bauer DJM; Scheiner B; Balcar L; Semmler G; Schwarz M; Marculescu R; Dannenberg V; Trauner M; Mandorfer M; Reiberger T
    JHEP Rep; 2024 Jan; 6(1):100954. PubMed ID: 38125301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of response to beta-blockers by expression of βArr2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients.
    Trebicka J; von Heydebrand M; Lehmann J; Tofteng F; Busk T; Jensen HL; Rohde J; Reiberger T; Mortensen C; Schierwagen R; Klein S; Møller S; Bendtsen F; Krag A
    J Hepatol; 2016 Jun; 64(6):1265-73. PubMed ID: 26827791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An impaired pituitary-adrenal signalling axis in stable cirrhosis is linked to worse prognosis.
    Hartl L; Simbrunner B; Jachs M; Wolf P; Bauer DJM; Scheiner B; Balcar L; Semmler G; Schwarz M; Marculescu R; Trauner M; Mandorfer M; Reiberger T
    JHEP Rep; 2023 Aug; 5(8):100789. PubMed ID: 37484210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.
    Scheiner B; Balcar L; Nussbaumer RJ; Weinzierl J; Paternostro R; Simbrunner B; Hartl L; Jachs M; Bauer D; Stättermayer AF; Semmler G; Pinter M; Ay C; Quehenberger P; Trauner M; Reiberger T; Lisman T; Mandorfer M
    J Hepatol; 2022 May; 76(5):1090-1099. PubMed ID: 35066090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulated biomarkers of innate and adaptive immunity predict infections and disease progression in cirrhosis.
    Simbrunner B; Hartl L; Jachs M; Bauer DJM; Scheiner B; Hofer BS; Stättermayer AF; Marculescu R; Trauner M; Mandorfer M; Reiberger T
    JHEP Rep; 2023 May; 5(5):100712. PubMed ID: 37035457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic Response to Carvedilol is Maintained for Long Periods and Leads to Better Clinical Outcome in Cirrhosis: A Prospective Study.
    Kirnake V; Arora A; Gupta V; Sharma P; Singla V; Bansal N; Goyal M; Chawlani R; Kumar A
    J Clin Exp Hepatol; 2016 Sep; 6(3):175-185. PubMed ID: 27746613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.